SRR934922
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.509855453350852
- age_years
- 30
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.574
- INTERFERON_ALPHA_RESPONSE+0.481
- MYC_TARGETS_V1+0.466
- E2F_TARGETS+0.462
- G2M_CHECKPOINT+0.433
- TGF_BETA_SIGNALING+0.411
- MITOTIC_SPINDLE+0.408
- INTERFERON_GAMMA_RESPONSE+0.396
- ANDROGEN_RESPONSE+0.343
- OXIDATIVE_PHOSPHORYLATION+0.338
Top 10 suppressed
- KRAS_SIGNALING_DN-0.485
- SPERMATOGENESIS-0.300
- MYOGENESIS-0.294
- PANCREAS_BETA_CELLS-0.203
- HEDGEHOG_SIGNALING-0.129
- ESTROGEN_RESPONSE_EARLY-0.128
- UV_RESPONSE_UP-0.126
- APICAL_SURFACE-0.121
- XENOBIOTIC_METABOLISM-0.121
- ESTROGEN_RESPONSE_LATE-0.114
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 31A652B1-3BEB-4D78-BCA0-4C153EBC41E8 | — | — | 0.910 |
| 2 | SRR934878 | — | — | 0.909 |
| 3 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.907 |
| 4 | SRR934925 | — | — | 0.906 |
| 5 | 2F382D6A-B26F-450A-A156-9407D14538CD | — | — | 0.899 |
| 6 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.895 |
| 7 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.893 |
| 8 | SRR934895 | — | — | 0.892 |
| 9 | SRR934942 | — | — | 0.891 |
| 10 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.574 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.481 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.466 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.462 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.433 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.411 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.408 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.396 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.343 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.338 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.338 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.317 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.315 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.304 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.297 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.259 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.241 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.229 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.222 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |